SCHEMBL4015160

SCHEMBL4015160

N#Cc1n[nH]c2ccc(S(=O)(=O)Oc3ccc(Cl)c(Cl)c3)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APEX1 P27695 1/20 0.47
▸ ALPL P05186 6/20 0.36
▸ ALPI P09923 5/20 0.36
▸ SLC22A12 Q96S37 1/20 0.35
▸ CCR2 P41597 1/20 0.35
▸ NTRK1 P04629 2/20 0.34
▸ CYP11B1 P15538 1/20 0.34
▸ CYP11B2 P19099 1/20 0.34
▸ HTR2A P28223 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ PTGS1 P23219 1/20 0.32
▸ PTGS2 P35354 1/20 0.32
▸ FPR2 P25090 1/20 0.32
▸ PROKR1 Q8TCW9 1/20 0.32
▸ PLA2G7 Q13093 1/20 0.32
▸ LGALS8 O00214 1/20 0.32
▸ LGALS3 P17931 1/20 0.32
▸ NTRK3 Q16288 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4004276 0.95 APEX1 (0.50) APEX1ALPLALPISLC22A12CCR2
SCHEMBL4007111 0.84 APEX1 (0.52) APEX1ALPLALPIHTR2ASLC6A4
SCHEMBL4013654 0.82 APEX1 (0.50) APEX1ALPLALPICCR2IDO1
SCHEMBL4006545 0.82 APEX1 (0.50) APEX1ALPLALPIHTR2ASLC6A4
SCHEMBL4008318 0.82 APEX1 (0.50) APEX1ALPLALPIHTR2ASLC6A4
SCHEMBL4009669 0.81 NTRK1 (0.41) ALPLALPISLC22A12NTRK1NTRK3
SCHEMBL4015098 0.80 APEX1 (0.56) APEX1ALPLALPICYP11B1CYP11B2
SCHEMBL4006453 0.80 APEX1 (0.50) APEX1ALPLIDO1NTRK3
SCHEMBL4008733 0.79 APEX1 (0.46) APEX1NTRK1KCNH2LGALS8LGALS3
SCHEMBL4006373 0.79 NTRK1 (0.41) ALPLALPINTRK1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 — — US disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 — — US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 — — US disclosed
EP-1487803-A1 INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY Aventis Pharma S.A. (FR) 2004-12-22 — — EP disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 — — US disclosed
WO-2003078402-A1 INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY AVENTIS PHARMA S.A. (FR) 2003-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 APEX1 2215/4885ALPL 2118/4885ALPI 2987/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 APEX1 2168/4885ALPL 2355/4885ALPI 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback